I found the numbers in
this article rather fascinating. Drugs such as Rituximab gross around 5 billions a year. If we say each cancer/RA patient uses RTX for ten grand each, than the numbers show that there are 500,000 whom get RTX yearly. In both B cell cancer and RA there's probably a higher prevalence of PWME. Let's say just 0,4% of them had ME prior to the cancer, or concurrent with the RA. That would mean that
every year, 2000 patients with ME have been getting Rituximab. Two thousand yearly. And when one of them just happened to be a ME patient at Mella/Fluge's departement, they said to themselves "Hmmm, we ought to investigate what's behind this drastic improvement". Co-incidence that it got know.
So, if (over) 2000 ME patients have got the drug in other situations, and the news that it helps recently broke, what than about other RA drugs? What about other immune modulating drugs, which works for syndromes much like ME?
How could we know that other RA / MS drugs quenching the inflammatory/autoimmunity in those groups wont work for us as well?
I really think we've got a sea of opportunities here! I call for more pilot studies on other immune modulating drugs. Preferably those which have shown efficacy against MS or RA. Small pilot studies.